AxoGen (AXGN) stock price today was up over 6%. AxoGen is a developer and marketer of surgical solutions for peripheral nerve injuries. Recently, AxoGen announced positive topline results for Avance Nerve Graft product. Chairman and CEO Karen Zaderej weighs in on nerve grafting and the recent AxoGen earnings report that indicated $31M in revenue. How will this healthcare stock perform moving forward?
13 May 2022
The Watch List
20 Apr 2022
The Watch List
20 May 2022
The Watch List
28 Apr 2022
The Watch List
01 Mar 2022
Trading 360
04 Apr 2022
Market On Close
16 Mar 2022